Related Experiment Video
Updated: Aug 1, 2026
08:54
Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
19.4K
Special Issue: Antifungal Agents Recently Approved or under Development.
Ana Espinel-Ingroff1, Eric Dannaoui2,3
1Virginia Commonwealth University Medical Center, Richmond, VA 23219, USA.
Journal of Fungi (Basel, Switzerland)
|April 3, 2021
Summary
This special issue reviews recently approved and emerging antifungal agents. It covers current knowledge and future perspectives on combating fungal infections.
Area of Science:
- Medical Mycology
- Pharmacology
Background:
- Fungal infections pose a significant global health threat, with increasing incidence of drug-resistant strains.
- The pipeline for new antifungal therapies has been historically limited, necessitating urgent innovation.
Discussion:
- This special issue consolidates recent advancements in antifungal drug discovery and development.
- It examines novel mechanisms of action and strategies to overcome antifungal resistance.
- Key approved agents and promising candidates in clinical trials are highlighted.
Key Insights:
- Several new antifungal agents with novel mechanisms have recently gained approval or are in late-stage development.
- Combination therapies and host-directed strategies show potential for improved treatment outcomes.
- Understanding the evolving landscape of antifungal resistance is crucial for effective therapeutic selection.
Outlook:
- Future research should focus on broadening the spectrum of activity and improving the safety profiles of antifungal drugs.
- Development of agents targeting emerging resistant fungal pathogens is a priority.
- Personalized medicine approaches may optimize antifungal therapy in the future.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...